Skip to content

Partial Breast Irradiation (PBI) for Selected Patients With Early Invasive or Non-Invasive Breast Cancer

Partial Breast Irradiation (PBI) for Selected Patients With Early Invasive or Non-Invasive Breast Cancer: A Phase I Feasibility/Pilot Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00694577
Enrollment
324
Registered
2008-06-10
Start date
2003-09-30
Completion date
2021-06-30
Last updated
2022-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ductal Breast Cancer

Keywords

non-invasive breast cancer, early invasive breast cancer, radiation, PBI

Brief summary

The purpose of this study is to determine the feasibility of partial breast irradiation in participants with early invasive or non-invasive breast cancer.

Detailed description

* In this study, radiotherapy is given only to a portion of the breast around the tumor bed using external radiation treatments. This approach is called partial breast irradiation. * Participants will undergo a planning session for the radiation treatments. This planning will be done by CT scan days or weeks before the start of treatment. This planning process is the same as that used to plan conventional radiation therapy treatments. * Radiation therapy will begin 4-12 weeks after the last surgery of the breast in individuals not receiving chemotherapy first. For individuals receiving chemotherapy before radiation therapy, radiation therapy will start 2-6 weeks after ending chemotherapy. * We will be studying three levels of radiation doses to see which is best. The dose the participant receives will depend upon when they are enrolled on the trial. * Participants will receive radiation treatment twice each day for 4 or 5 treatment days, with an overall treatment time of one week.

Interventions

RADIATIONPartial Breast Irradiation using 32 Gy / 8 fractions

32 Gy-8 Treatments, 4 Treatment Days

RADIATIONPartial Breast Irradiation using 36 Gy / 9 fractions

36 Gy- 9 Treatments, 4 1/2 Treatment Days

RADIATIONPartial Breast Irradiation using 40 Gy /10 fractions

40 Gy-10 Treatments, 5 Treatment days

Sponsors

Dana-Farber Cancer Institute
CollaboratorOTHER
Brigham and Women's Hospital
CollaboratorOTHER
Beth Israel Deaconess Medical Center
CollaboratorOTHER
Boston Medical Center
CollaboratorOTHER
Massachusetts General Hospital
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Histologically confirmed unicentric Stage I Invasive Ductal breast cancer. Histologically negative tumor margin 2mm or more from any inked edges, or no tumor in re-excision specimen or final shaved specimen. * Patient may have been treated with adjuvant chemotherapy, or be on adjuvant hormonal therapy or begin hormonal therapy following XRT * 18 years of age or older * ECOG Performance Status 0 * Required laboratory data as outlined in the protocol

Exclusion criteria

* Multicentric IDC of the breast defined as discontiguous tumors separated by at least 5cm of uninvolved tissue * Multifocal IDC of the breast, defined as discontiguous discrete foci of invasive carcinoma, separated by uninvolved intervening tissue, but within an overall span of 5cm, or within the same breast quadrant or subareolar central region * Tumor \> 2.0cm, nodal involvement, or metastatic involvement * Histological evidence of: lymphovascular invasion; blood vessel invasion; extensive intraductal component; invasive lobular carcinoma and infiltrating carcinoma of mixed ductal and lobular type; DCIS with microinvasion and DCIS suspicious for microinvasion; infiltrating micropapillary carcinoma * Known mutation carrier, including BRCA1 and BRCA2 * History of cosmetic or reconstructive breast surgery * Psychiatric illness which would prevent the patient from giving informed consent * Medical conditions such as uncontrolled infection, uncontrolled diabetes mellitus or connective tissue disease * Participants with a currently active second malignancy other than non-melanoma skin cancers * Patients with diffuse (\> 1 quadrant or \>5cm) suspicious microcalcifications * Women who are pregnant

Design outcomes

Primary

MeasureTime frameDescription
Feasibility and Local Control of Early Breast Cancer Treated by Partial Breast Irradiation Using Different Radiation Doses Determined by Completion.10 yearsFeasibility and local control of early breast cancer treated by partial breast irradiation using different radiation doses. Number of patients who completed partial breast irradiation was used to determine feasibility.
Number of Patients Who Presented With Local Recurrence in the Same Breast Which Received Treatment and Confirmed by Positive Biopsy10 yearsRisk of local failure after PBI determined by number of patients who presented with local recurrence in the same breast confirmed by positive biopsy

Secondary

MeasureTime frameDescription
Number of Patients Who Presented With Moderate to Severe Composite Toxicity as an Endpoint8 yearsNumber of patients who presented with moderate to severe composite toxicity as an endpoint
Number of Patients Who Developed Moderate to Severe Breast Fibrosis After Partial Breast Irradiation8 yearsRate of moderate to severe breast fibrosis determined by number of patients who developed moderate to severe breast fibrosis after partial breast irradiation according to radiation dose level
Number of Patients Who Had Poor/Fair Cosmetic Outcome After Partial Breast Irradiation8 yearsNumber of patients who had poor/fair cosmetic outcome after partial breast irradiation. Other participants had excellent/good cosmetic outcomes.
To Evaluate Patient Satisfaction8 yearsA survey asking the patient about her level of satisfaction with her PBI treatment. Patients who are totally satisfied with their appearance.

Countries

United States

Participant flow

Participants by arm

ArmCount
Group 1
Study Participants 1-100 Partial Breast Irradiation using 32 Gy / 8 fractions, BID: 4 Treatment Days, within 1 week
98
Group 2
Study Participants 101-200 Partial Breast Irradiation using 36 Gy / 9 fractions, BID: 4 1/2 Treatment Days, within 1 week
101
Group 3
Study Participants 201-330 Partial Breast Irradiation using 40 Gy / 10 fractions, BID: 5 Treatment Days, within 1 week
124
Total323

Baseline characteristics

CharacteristicGroup 1Group 2Group 3Total
Age, Continuous61 years61 years60 years61 years
Number of patients with triple negative cancer (ER-/PR-/HER2-)10 Participants4 Participants2 Participants16 Participants
Race and Ethnicity Not Collected0 Participants
Region of Enrollment
United States
98 participants101 participants124 participants323 participants
Sex: Female, Male
Female
98 Participants101 Participants124 Participants323 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
0 / 980 / 990 / 124
other
Total, other adverse events
0 / 980 / 990 / 124
serious
Total, serious adverse events
0 / 980 / 990 / 124

Outcome results

Primary

Feasibility and Local Control of Early Breast Cancer Treated by Partial Breast Irradiation Using Different Radiation Doses Determined by Completion.

Feasibility and local control of early breast cancer treated by partial breast irradiation using different radiation doses. Number of patients who completed partial breast irradiation was used to determine feasibility.

Time frame: 10 years

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Group 1Feasibility and Local Control of Early Breast Cancer Treated by Partial Breast Irradiation Using Different Radiation Doses Determined by Completion.98 Participants
Group 2Feasibility and Local Control of Early Breast Cancer Treated by Partial Breast Irradiation Using Different Radiation Doses Determined by Completion.101 Participants
Group 3Feasibility and Local Control of Early Breast Cancer Treated by Partial Breast Irradiation Using Different Radiation Doses Determined by Completion.124 Participants
Primary

Number of Patients Who Presented With Local Recurrence in the Same Breast Which Received Treatment and Confirmed by Positive Biopsy

Risk of local failure after PBI determined by number of patients who presented with local recurrence in the same breast confirmed by positive biopsy

Time frame: 10 years

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Group 1Number of Patients Who Presented With Local Recurrence in the Same Breast Which Received Treatment and Confirmed by Positive Biopsy6 Participants
Group 2Number of Patients Who Presented With Local Recurrence in the Same Breast Which Received Treatment and Confirmed by Positive Biopsy4 Participants
Group 3Number of Patients Who Presented With Local Recurrence in the Same Breast Which Received Treatment and Confirmed by Positive Biopsy1 Participants
Secondary

Number of Patients Who Developed Moderate to Severe Breast Fibrosis After Partial Breast Irradiation

Rate of moderate to severe breast fibrosis determined by number of patients who developed moderate to severe breast fibrosis after partial breast irradiation according to radiation dose level

Time frame: 8 years

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Group 1Number of Patients Who Developed Moderate to Severe Breast Fibrosis After Partial Breast Irradiation37 Participants
Group 2Number of Patients Who Developed Moderate to Severe Breast Fibrosis After Partial Breast Irradiation52 Participants
Group 3Number of Patients Who Developed Moderate to Severe Breast Fibrosis After Partial Breast Irradiation83 Participants
Secondary

Number of Patients Who Had Poor/Fair Cosmetic Outcome After Partial Breast Irradiation

Number of patients who had poor/fair cosmetic outcome after partial breast irradiation. Other participants had excellent/good cosmetic outcomes.

Time frame: 8 years

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Group 1Number of Patients Who Had Poor/Fair Cosmetic Outcome After Partial Breast Irradiation21 Participants
Group 2Number of Patients Who Had Poor/Fair Cosmetic Outcome After Partial Breast Irradiation36 Participants
Group 3Number of Patients Who Had Poor/Fair Cosmetic Outcome After Partial Breast Irradiation56 Participants
Secondary

Number of Patients Who Presented With Moderate to Severe Composite Toxicity as an Endpoint

Number of patients who presented with moderate to severe composite toxicity as an endpoint

Time frame: 8 years

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Group 1Number of Patients Who Presented With Moderate to Severe Composite Toxicity as an Endpoint46 Participants
Group 2Number of Patients Who Presented With Moderate to Severe Composite Toxicity as an Endpoint67 Participants
Group 3Number of Patients Who Presented With Moderate to Severe Composite Toxicity as an Endpoint100 Participants
Secondary

To Evaluate Patient Satisfaction

A survey asking the patient about her level of satisfaction with her PBI treatment. Patients who are totally satisfied with their appearance.

Time frame: 8 years

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Group 1To Evaluate Patient Satisfaction94 Participants
Group 2To Evaluate Patient Satisfaction94 Participants
Group 3To Evaluate Patient Satisfaction110 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026